The TSH/Thyroid Hormones Axis and Breast Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Feb 15

PMID 35160139

Authors

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Breast cancer, the most prevalent female carcinoma, is characterized by the expression of steroid nuclear receptors in a subset of cases. The most important nuclear receptor with prognostic and therapeutic implications is the Estrogen Receptor (ER), which is expressed in about three out of four breast cancers. The Progesterone Receptor (PR) and the Androgen Receptor (AR) are also commonly expressed. Moreover, non-steroid nuclear receptors, including the vitamin D receptor (VDR) and the thyroid receptors (TRs), are also present in breast cancers and have pathophysiologic implications. Circulating thyroid hormones may influence breast cancer risk and breast cancer cell survival, through ligating their canonical receptors TRα and TRβ but also through additional membrane receptors that are expressed in breast cancer. The expression of TR subtypes and their respective isotypes have diverse effects in breast cancers through co-operation with ER and influence on other cancer-associated pathways. Other components of the TSH/thyroid hormone axis, such as TSH and selenoiodinase enzymes, have putative effects in breast cancer pathophysiology. This paper reviews the pathophysiologic and prognostic implications of the thyroid axis in breast cancer and provides a brief therapeutic perspective.

Citing Articles

Triiodothyronine (T3) increases the expression of the amphiregulin (AREG) oncogene by activating extranuclear pathways in MCF-7 breast cancer cells.

De Sibio M, Moretto F, Olimpio R, de Oliveira M, Mathias L, Peghinelli V Arch Endocrinol Metab. 2025; 68(Spec Issue):e240094.

PMID: 39876971 PMC: 11771754. DOI: 10.20945/2359-4292-2023-0094.

Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer.

Hantusch B, Kenner L, Stanulovic V, Hoogenkamp M, Brown G Int J Mol Sci. 2024; 25(17).

PMID: 39273194 PMC: 11394715. DOI: 10.3390/ijms25179245.

Resolution of Breast Cancer in a Patient With Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor With the Combination of Chemotherapy and Lanreotide.

Komai S, Harai N, Tahara I, Nakayama Y, Tsuchiya K Cureus. 2024; 16(8):e66221.

PMID: 39238765 PMC: 11374449. DOI: 10.7759/cureus.66221.

The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters.

Varzaru V, Eftenoiu A, Vlad D, Vlad C, Moatar A, Popescu R Life (Basel). 2024; 14(4).

PMID: 38672729 PMC: 11051489. DOI: 10.3390/life14040458.

Prospective role of lusianthridin in attenuating cadmium-induced functional and cellular damage in rat thyroid.

Gao T, Luo S, Li H, Su Z, Wen Q Heliyon. 2024; 10(5):e27080.

PMID: 38449627 PMC: 10915401. DOI: 10.1016/j.heliyon.2024.e27080.

References

Sar P, Peter R, Rath B, Mohapatra A, Mishra S . 3, 3'5 Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements. PLoS One. 2011; 6(6):e20861. PMC: 3110202. DOI: 10.1371/journal.pone.0020861. View

Govindaraj V, Singh Yaduvanshi N, Krishnamachar H, Rao A . Expression of thyroid-stimulating hormone receptor, octamer-binding transcription factor 4, and intracisternal A particle-promoted polypeptide in human breast cancer tissues. Horm Mol Biol Clin Investig. 2014; 9(3):173-8. DOI: 10.1515/hmbci-2011-0130. View

Sloan E, Pouliot N, Stanley K, Chia J, Moseley J, Hards D . Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006; 8(2):R20. PMC: 1557720. DOI: 10.1186/bcr1398. View

Charalampoudis P, Agrogiannis G, Kontzoglou K, Kouraklis G, Sotiropoulos G . Thyroid hormone receptor alpha (TRa) tissue expression in ductal invasive breast cancer: A study combining quantitative immunohistochemistry with digital slide image analysis. Eur J Surg Oncol. 2017; 43(8):1428-1432. DOI: 10.1016/j.ejso.2017.05.012. View

Beer A, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P . Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008; 49(2):255-9. DOI: 10.2967/jnumed.107.045526. View

Sirakov M, Skah S, Nadjar J, Plateroti M . Thyroid hormone's action on progenitor/stem cell biology: new challenge for a classic hormone?. Biochim Biophys Acta. 2012; 1830(7):3917-27. DOI: 10.1016/j.bbagen.2012.07.014. View

Tosovic A, Bondeson A, Bondeson L, Ericsson U, Malm J, Manjer J . Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res. 2010; 12(3):R33. PMC: 2917028. DOI: 10.1186/bcr2587. View

Cristofanilli M, Yamamura Y, Kau S, Bevers T, Strom S, Patangan M . Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005; 103(6):1122-8. DOI: 10.1002/cncr.20881. View

Guigon C, Kim D, Zhu X, Zhao L, Cheng S . Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology. 2010; 151(11):5528-36. PMC: 2954723. DOI: 10.1210/en.2010-0475. View

10.

Shao Z, Sheikh M, Rishi A, Dawson M, Li X, Wilber J . Thyroid hormone enhancement of estradiol stimulation of breast carcinoma proliferation. Exp Cell Res. 1995; 218(1):1-8. DOI: 10.1006/excr.1995.1124. View

11.

Conde S, Luvizotto R, De Sibio M, Nogueira C . Thyroid hormone status interferes with estrogen target gene expression in breast cancer samples in menopausal women. ISRN Endocrinol. 2014; 2014:317398. PMC: 3950583. DOI: 10.1155/2014/317398. View

12.

Debski M, Pachucki J, Ambroziak M, Olszewski W, Bar-Andziak E . Human breast cancer tissue expresses high level of type 1 5'-deiodinase. Thyroid. 2007; 17(1):3-10. DOI: 10.1089/thy.2006.0012. View

13.

Welsh J . Function of the vitamin D endocrine system in mammary gland and breast cancer. Mol Cell Endocrinol. 2017; 453:88-95. PMC: 5538720. DOI: 10.1016/j.mce.2017.04.026. View

14.

Kress E, Skah S, Sirakov M, Nadjar J, Gadot N, Scoazec J . Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis. Gastroenterology. 2010; 138(5):1863-74. DOI: 10.1053/j.gastro.2010.01.041. View

15.

Tosovic A, Bondeson A, Bondeson L, Ericsson U, Manjer J . T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study. BMC Cancer. 2014; 14:536. PMC: 4131035. DOI: 10.1186/1471-2407-14-536. View

16.

Nogueira C, Brentani M . Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996; 59(3-4):271-9. DOI: 10.1016/s0960-0760(96)00117-3. View

17.

Park J, Zhao L, Willingham M, Cheng S . Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β. Mol Carcinog. 2016; 56(2):489-498. PMC: 7886287. DOI: 10.1002/mc.22511. View

18.

Voutsadakis I . Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020; 14(1):16-26. DOI: 10.1016/j.hemonc.2020.08.005. View

19.

Brent G . Mechanisms of thyroid hormone action. J Clin Invest. 2012; 122(9):3035-43. PMC: 3433956. DOI: 10.1172/JCI60047. View

20.

Kress E, Rezza A, Nadjar J, Samarut J, Plateroti M . The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. J Biol Chem. 2008; 284(2):1234-41. DOI: 10.1074/jbc.M806548200. View